Skip to main content

Name
Charmi Shah

Fri, 09/25/2020 - 17:50

Great post Michaela, you effectively summarized “The Imatinib Story” by highlighting Dr. Lee’s key points and our class discussion!

One part of the discussion that amazed me is Dr. Lee’s discussion about the first time he used Imatinib and how it was the first day it was formally approved by Health Canada, but this was just a coincidence because he had already arranged approval from before to use Imatinib on that day. This showed me the confidence he had in the drug’s mechanism and accordingly, his patient was able to benefit from Imatinib for some time.

A concern for Imatinib is in regards to patients having intolerance or resistance to the drug. It would be interesting to see how the effects of combination therapy may alter these concerns of drug intolerance or resistance. From the articles, it was interesting to read that second-generation tyrosine kinase inhibitors (TKI) overcome most of the mutations that are correlated to Imatinib resistance. Ponatinib is a third-generation TKI that patients may be considered for if they have intolerance or resistance to the second-generation TKIs, namely, dasatinib or nilotinib. Currently, the safe dosage of ponatinib is being studied. I am excited to see what we learn about the survival rates for patients from these second and third-generation tyrosine kinase inhibitors, in comparison to the effects seen by Imatinib.

Dr. Lee’s lecture sparked my interest in Imatinib and I am eager to see the future evolution of tyrosine kinase inhibitor drugs. 

Name
Charmi Shah

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.